Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women

Carcinogenesis

Volumn 30, Issue 4, 2009, Pages 626-635

  Cote, Michele L ^a,b   Yoo, Wonsuk ^b   Wenzlaff, Angela S ^a   Prysak, Geoffrey M ^a   Santer, Susan K ^a   Claeys, Gina B ^a   Van Dyke, Alison L ^a,b   Land, Susan J ^a,b   Schwartz, Ann G ^a,b  

^a KARMANOS CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 17; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; XRCC1 PROTEIN;

ADULT; AGED; ANAMNESIS; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; DNA REPAIR; ESTROGEN METABOLISM; FAMILY HISTORY; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; WOMEN'S HEALTH;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; ESTROGENS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; TOBACCO;

EID: 64349109466     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp033     Document Type: Article

References (60)

1. Ries,L.A.G. et al. (eds) (2008) SEER Cancer Statistics Review, 1975-2005. National Cancer Institute, Bethesda, MD.
2. Zang,E.A. et al. (1996) Differences in lung cancer risk between men and women: Examination of the evidence. J. Natl Cancer Inst., 88, 183-192.
3. Ryberg,D. et al. (1994) Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res., 54, 5801-5803.
4. Mollerup,S. et al. (1999) Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res., 59, 3317-3320.
5. Kure,E.H. et al. (1996) p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels. Carcinogenesis, 17, 2201-2205.
6. Tam,I.Y. et al. (2006) Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin. Cancer Res., 12, 1647-1653.
7. Liu,Y. et al. (2005) Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women: A large-scale population-based cohort study. Int. J. Cancer, 117 662-666.
8. Taioli,E. et al. (1994) Re: Endocrine factors and adenocarcinoma of the lung in women. J. Natl Cancer Inst., 86, 869-870.
9. Kreuzer,M. et al. (2003) Hormonal factors and risk of lung cancer among women? Int. J. Epidemiol., 32, 263-271.
10. Schabath,M.B. et al. (2004) Hormone replacement therapy and lung cancer risk: A case-control analysis. Clin. Cancer Res., 10, 113-123.
11. Kabat,G.C. et al. (2007) Reproductive and hormonal factors and risk of lung cancer in women: A prospective cohort study. Int. J. Cancer, 120, 2214-2220.
12. Schwartz,A.G. et al. (2007) Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J. Clin. Oncol., 25, 5785-5792.
13. Beattie,C.W. et al. (1985) Steroid receptors in human lung cancer. Cancer Res., 45, 4206-4214.
14. Cagle,P.T. et al. (1990) Estrogen and progesterone receptors in bronchogenic carcinoma. Cancer Res., 50, 6632-6635.
15. Chaudhuri,P.K. et al. (1982) Steroid receptors in human lung cancer cytosols. Cancer Lett., 16, 327-332.
16. Kaiser,U. et al. (1996) Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int. J. Cancer, 67, 357-364.
17. Mollerup,S. et al. (2002) Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer, 37 153-159.
18. Stabile,L.P. et al. (2002) Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res., 62 2141-2150.
19. Kawai,H. et al. (2005) Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin. Cancer Res. 11, 5084-5089.
20. Schwartz,A.G. et al. (2005) Nuclear estrogen receptor beta in lung cancer: Expression and survival differences by sex. Clin. Cancer Res. 11, 7280-7287.
21. Skov,B.G. et al. (2008) Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer, 59, 88-94.
22. Wu,C.T. et al. (2005) The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J. Thorac. Cardiovasc. Surg., 130, 979-986.
23. Hung,R.J. et al. (2005) Genetic polymorphisms in the base excision repair pathway and cancer risk: A HuGE review. Am. J. Epidemiol., 162, 925-942.
24. Spivack,S.D. et al. (2003) Phase I and II carcinogen metabolism gene expression in human lung tissue and tumors. Clin. Cancer Res. 9, 6002-6011.
25. Ball,P. et al. (1980) Catecholoestrogens (2-and 4-hydroxyoestrogens): Chemistry, biogenesis, metabolism, occurrence and physiological significance. Acta Endocrinol. Suppl. (Copenh.), 232, 1-127.
26. Colilla,S. et al. (2005) Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenet. Genomics, 15, 393-398.
27. Martucci,C.P. et al. (1993) P450 enzymes of estrogen metabolism. Pharmacol. Ther., 57, 237-257.
28. Feigelson,H.S. et al. (1998) Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res., 58, 585-587.
29. Picado-Leonard,J. et al. (1987) Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): Similarity with the gene for P450c21. DNA, 6, 439-448.
30. Means,G.D. et al. (1989) Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. J. Biol. Chem., 264, 19385-19391.
31. Drakoulis,N. et al. (1994) Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: Exon-7 mutation (4889 A to G), and a T to C mutation in the 3′-flanking region. Clin. Investig., 72, 240-248.
32. Wenzlaff,A.S. et al. (2005) CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: A population-based study. Carcinogenesis, 26, 2207-2212.
33. Bock,C.H. et al. (2005) NQO1 T allele associated with decreased risk of later age at diagnosis lung cancer among never smokers: Results from a population-based study. Carcinogenesis, 26, 381-386.
34. Wenzlaff,A.S. et al. (2005) GSTM1, GSTT1 and GSTP1 polymorphisms, environmental tobacco smoke exposure and risk of lung cancer among never smokers: A population-based study. Carcinogenesis, 26, 395-401.
35. Benhamou,S. et al. (2002) Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis, 23, 1343-1350.
36. Raimondi,S. et al. (2006) Meta- and pooled analysis of GSTT1 and lung cancer: A HuGE-GSEC review. Am. J. Epidemiol., 164, 1027-1042.
37. Schwartz,A.G. et al. (2007) The molecular epidemiology of lung cancer. Carcinogenesis, 28, 507-518.
38. Han,W. et al. (2005) Estrogen receptor alpha increases basal and cigarette smoke extract-induced expression of CYP1A1 and CYP1B1, but not GSTP1, in normal human bronchial epithelial cells. Mol. Carcinog., 44, 202-211.
39. Polymeropoulos,M.H. et al. (1991) Tetranucleotide repeat polymorphism at the human aromatase cytochrome P-450 gene (CYP19). Nucleic Acids Res., 19, 195.
40. Gennari,L. et al. (2004) A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. J. Clin. Endocrinol. Metab., 89, 2803-2810.
41. Dick,I.M. et al. (2005) Association of an aromatase TTTA repeat polymorphism with circulating estrogen, bone structure, and biochemistry in older women. Am. J. Physiol. Endocrinol. Metab., 288, E989-E995.
42. Baxter,S.W. et al. (2001) Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis, 22, 347-349.
43. Healey,C.S. et al. (2000) Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis 21, 189-193.
44. Cussenot,O. et al. (2007) Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: The hidden face of estrogens. J. Clin. Oncol., 25, 3596-3602.
45. Li,L. et al. (2004) No association between a tetranucleotide repeat polymorphism of CYP19 and prostate cancer. Cancer Epidemiol. Biomarkers Prev., 13, 2280-2281.
46. Paynter,R.A. et al. (2005) CYP19 (aromatase) haplotypes and endometrial cancer risk. Int. J. Cancer, 116, 267-274.
47. Lachman,H.M. et al. (1996) Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6, 243-250.
48. Palmatier,M.A. et al. (1999) Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles. Biol. Psychiatry, 46, 557-567.
49. Zienolddiny,S. et al. (2008) A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. Carcinogenesis, 29, 1164-1169.
50. Carey,A.H. et al. (1994) Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum. Mol. Genet., 3, 1873-1876.
51. Olson,S.H. et al. (2007) Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: A HuGE review. Am. J. Epidemiol., 165, 235-245.
52. Gaudet,M.M. et al. (2008) Genetic variation in CYP17 and endometrial cancer risk. Hum. Genet., 123, 155-162.
53. Setiawan,V.W. et al. (2007) CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol. Biomarkers Prev., 16, 2237-2246.
54. Hanna,I.H. et al. (2000) Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: Association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res., 60 3440-3444.
55. Etzel,C.J. et al. (2008) Development and validation of a lung cancer risk prediction model for African-Americans. Cancer Prev. Res. 1, 255-265.
56. Cassidy,A. et al. (2007) Lung cancer risk prediction: A tool for early detection. Int. J. Cancer, 120, 1-6.
57. Prindiville,S.A. et al. (2003) Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction. Cancer Epidemiol. Biomarkers Prev., 12, 987-993.
58. Bach,P.B. et al. (2003) Variations in lung cancer risk among smokers. J. Natl Cancer Inst., 95, 470-478.
59. Cassidy,A. et al. (2008) The LLP risk model: An individual risk prediction model for lung cancer. Br. J. Cancer, 98, 2702-76.
60. Spitz,M.R. et al. (2007) A risk model for prediction of lung cancer. J. Natl Cancer Inst., 99, 715-726.